» Authors » Anne-Lise Borresen-Dale

Anne-Lise Borresen-Dale

Explore the profile of Anne-Lise Borresen-Dale including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 326
Citations 34464
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Fleischer T, Haugen M, Ankill J, Silwal-Pandit L, Borresen-Dale A, Hedenfalk I, et al.
Mol Oncol . 2024 Apr; 18(8):2042-2059. PMID: 38671580
Treatment with the anti-angiogenic drug bevacizumab in addition to chemotherapy has shown efficacy for breast cancer in some clinical trials, but better biomarkers are needed to optimally select patients for...
2.
Nygaard V, Ree A, Dagenborg V, Borresen-Dale A, Edwin B, Fretland A, et al.
Cancer Res Commun . 2023 Mar; 3(2):235-244. PMID: 36968142
Significance: CLM is an important cause of colorectal cancer mortality where the majority of patients have yet to benefit from immunotherapies. In this study of gene expression profiling analyses, we...
3.
Castro-Mondragon J, Aure M, Lingjaerde O, Langerod A, Martens J, Borresen-Dale A, et al.
Nucleic Acids Res . 2022 Dec; 50(21):12131-12148. PMID: 36477895
Most cancer alterations occur in the noncoding portion of the human genome, where regulatory regions control gene expression. The discovery of noncoding mutations altering the cells' regulatory programs has been...
4.
Ahearn T, Zhang H, Michailidou K, Milne R, Bolla M, Dennis J, et al.
Breast Cancer Res . 2022 Jan; 24(1):2. PMID: 34983606
Background: Genome-wide association studies (GWAS) have identified multiple common breast cancer susceptibility variants. Many of these variants have differential associations by estrogen receptor (ER) status, but how these variants relate...
5.
Fores-Martos J, Cervera-Vidal R, Sierra-Roca J, Lozano-Asencio C, Fedele V, Cornelissen S, et al.
NPJ Breast Cancer . 2021 Sep; 7(1):118. PMID: 34508103
Polymorphisms in the PER3 gene have been associated with several human disease phenotypes, including sleep disorders and cancer. In particular, the long allele of a variable number of tandem repeat...
6.
Haugen M, Lingjaerde O, Hedenfalk I, Garred O, Borgen E, Loman N, et al.
JCO Precis Oncol . 2021 May; 5. PMID: 34036235
Purpose: Antiangiogenic therapy using bevacizumab has proven effective for a number of cancers; however, in breast cancer (BC), there is an unmet need to identify patients who benefit from such...
7.
Aure M, Fleischer T, Bjorklund S, Ankill J, Castro-Mondragon J, Borresen-Dale A, et al.
Genome Med . 2021 Apr; 13(1):72. PMID: 33926515
Background: Abnormal DNA methylation is observed as an early event in breast carcinogenesis. However, how such alterations arise is still poorly understood. microRNAs (miRNAs) regulate gene expression at the post-transcriptional...
8.
Dorling L, Carvalho S, Allen J, Gonzalez-Neira A, Luccarini C, Wahlstrom C, et al.
N Engl J Med . 2021 Jan; 384(5):428-439. PMID: 33471991
Background: Genetic testing for breast cancer susceptibility is widely used, but for many genes, evidence of an association with breast cancer is weak, underlying risk estimates are imprecise, and reliable...
9.
von der Lippe Gythfeldt H, Lien T, Tekpli X, Silwal-Pandit L, Borgen E, Garred O, et al.
Int J Cancer . 2020 Jun; 147(9):2515-2525. PMID: 32488909
Antiangiogenic drugs are potentially a useful supplement to neoadjuvant chemotherapy for a subgroup of patients with human epidermal growth factor receptor 2 (HER2) negative breast cancer, but reliable biomarkers for...
10.
Pladsen A, Nilsen G, Rueda O, Aure M, Borgan O, Liestol K, et al.
Commun Biol . 2020 Apr; 3(1):153. PMID: 32242091
Somatic copy number alterations are a frequent sign of genome instability in cancer. A precise characterization of the genome architecture would reveal underlying instability mechanisms and provide an instrument for...